Market Research Logo

Renal Diseases Drug Development Pipeline Review, 2018

Renal Diseases Drug Development Pipeline Review, 2018

Summary

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.

Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

This report “Renal Diseases Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Renal Diseases Report Coverage
    • Chronic Kidney Disease (Chronic Renal Failure) – Overview
    • Kidney Fibrosis – Overview
    • Polycystic Kidney Disease – Overview
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Overview
  • Therapeutics Development
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
      • Products under Development by Companies
        • Table Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
    • Kidney Fibrosis
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Kidney Fibrosis
        • Table Number of Products under Development for Kidney Fibrosis
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Kidney Fibrosis
        • Table Number of Products under Development by Companies, Kidney Fibrosis
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Kidney Fibrosis
      • Products under Development by Companies
        • Table Products under Development by Companies, Kidney Fibrosis
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Kidney Fibrosis
    • Polycystic Kidney Disease
      • Pipeline Overview
        • Table Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis
        • Table Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis
      • Pipeline by Companies
        • Table Figure 7: Number of Products under Development by Companies, Polycystic Kidney Disease
        • Table Number of Products under Development by Companies, Polycystic Kidney Disease
      • Pipeline by Universities/Institutes
        • Table Number of Products under Development by Universities/Institutes, Polycystic Kidney Disease
      • Products under Development by Companies
        • Table Products under Development by Companies, Polycystic Kidney Disease
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Polycystic Kidney Disease
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Pipeline Overview
        • Table Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Pipeline by Companies
        • Table Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Products under Development by Companies
        • Table Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
  • Therapeutics Assessment
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Assessment by Target
        • Table Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure)
      • Assessment by Mechanism of Action
        • Table Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure)
      • Assessment by Route of Administration
        • Table Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure)
      • Assessment by Molecule Type
        • Table Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
        • Table Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure)
    • Kidney Fibrosis
      • Assessment by Target
        • Table Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis
        • Table Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis
        • Table Number of Products by Stage and Target, Kidney Fibrosis
      • Assessment by Mechanism of Action
        • Table Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis
        • Table Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis
        • Table Number of Products by Stage and Mechanism of Action, Kidney Fibrosis
      • Assessment by Route of Administration
        • Table Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis
        • Table Number of Products by Stage and Route of Administration, Kidney Fibrosis
      • Assessment by Molecule Type
        • Table Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis
        • Table Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis
        • Table Number of Products by Stage and Molecule Type, Kidney Fibrosis
    • Polycystic Kidney Disease
      • Assessment by Target
        • Table Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease
        • Table Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease
        • Table Number of Products by Stage and Target, Polycystic Kidney Disease
      • Assessment by Mechanism of Action
        • Table Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease
        • Table Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease
        • Table Number of Products by Stage and Mechanism of Action, Polycystic Kidney Disease
      • Assessment by Route of Administration
        • Table Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease
        • Table Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease
        • Table Number of Products by Stage and Route of Administration, Polycystic Kidney Disease
      • Assessment by Molecule Type
        • Table Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease
        • Table Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease
        • Table Number of Products by Stage and Molecule Type, Polycystic Kidney Disease
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Assessment by Target
        • Table Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Number of Products by Stage and Target, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Assessment by Mechanism of Action
        • Table Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End- Stage Renal Disease or ESRD)
        • Table Number of Products by Stage and Mechanism of Action, End-Stage Kidney Disease (End- Stage Renal Disease or ESRD)
      • Assessment by Route of Administration
        • Table Number of Products by Stage and Route of Administration, End-Stage Kidney Disease (End- Stage Renal Disease or ESRD)
      • Assessment by Molecule Type
        • Table Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
        • Table Number of Products by Stage and Molecule Type, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
  • Companies Involved in Therapeutics Development
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Allena Pharmaceuticals Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Allena Pharmaceuticals Inc
      • Angion Biomedica Corp
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp
      • apceth Biopharma GmbH
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by apceth Biopharma GmbH
      • Arch Biopartners Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Arch Biopartners Inc
      • Astellas Pharma Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Astellas Pharma Inc
      • AstraZeneca Plc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by AstraZeneca Plc
      • Bayer AG
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG
      • Boehringer Ingelheim GmbH
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boehringer Ingelheim GmbH
      • Boryung Pharmaceutical Co Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boryung Pharmaceutical Co Ltd
      • Cellmid Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Cellmid Ltd
      • Corvidia Therapeutics Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Corvidia Therapeutics Inc
      • DiaMedica Therapeutics Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by DiaMedica Therapeutics Inc
      • Dimerix Bioscience Pty Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Dimerix Bioscience Pty Ltd
      • DURECT Corp
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by DURECT Corp
      • Evotec AG
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Evotec AG
      • GNI Group Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by GNI Group Ltd
      • KBP BioSciences Co Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by KBP BioSciences Co Ltd
      • Klotho Therapeutics Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Klotho Therapeutics Inc
      • Nash Pharmaceuticals Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Nash Pharmaceuticals Inc
      • Novartis AG
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Novartis AG
      • OPKO Health Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by OPKO Health Inc
      • Opsidio LLC
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Opsidio LLC
      • Otsuka Holdings Co Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Otsuka Holdings Co Ltd
      • Prolong Pharmaceuticals LLC
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prolong Pharmaceuticals LLC
      • ProMetic Life Sciences Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by ProMetic Life Sciences Inc
      • Reata Pharmaceuticals Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Reata Pharmaceuticals Inc
      • Resverlogix Corp
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Resverlogix Corp
      • Sanwa Kagaku Kenkyusho Co Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd
      • Sarfez Pharmaceuticals Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sarfez Pharmaceuticals Inc
      • Sphaera Pharma Pte Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sphaera Pharma Pte Ltd
      • Taisho Pharmaceutical Holdings Co Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Taisho Pharmaceutical Holdings Co Ltd
      • Theravance Biopharma Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Theravance Biopharma Inc
      • Unity Biotechnology Inc
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Unity Biotechnology Inc
      • Vascular BioSciences
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vascular BioSciences
      • VESSL Therapeutics Ltd
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by VESSL Therapeutics Ltd
      • Vicore Pharma AB
        • Table Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vicore Pharma AB
    • Kidney Fibrosis
      • AdAlta Ltd
        • Table Kidney Fibrosis – Pipeline by AdAlta Ltd
      • Angion Biomedica Corp
        • Table Kidney Fibrosis – Pipeline by Angion Biomedica Corp
      • BiOrion Technologies BV
        • Table Kidney Fibrosis – Pipeline by BiOrion Technologies BV
      • Cellmid Ltd
        • Table Kidney Fibrosis – Pipeline by Cellmid Ltd
      • Certa Therapeutics Pty Ltd
        • Table Kidney Fibrosis – Pipeline by Certa Therapeutics Pty Ltd
      • Epigen Biosciences Inc
        • Table Kidney Fibrosis – Pipeline by Epigen Biosciences Inc
      • Evotec AG
        • Table Kidney Fibrosis – Pipeline by Evotec AG
      • Galectin Therapeutics Inc
        • Table Kidney Fibrosis – Pipeline by Galectin Therapeutics Inc
      • GenKyoTex SA
        • Table Kidney Fibrosis – Pipeline by GenKyoTex SA
      • Genzyme Corp
        • Table Kidney Fibrosis – Pipeline by Genzyme Corp
      • iBio Inc
        • Table Kidney Fibrosis – Pipeline by iBio Inc
      • Isarna Therapeutics GmbH
        • Table Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH
      • Kadmon Corp LLC
        • Table Kidney Fibrosis – Pipeline by Kadmon Corp LLC
      • Les Laboratoires Servier SAS
        • Table Kidney Fibrosis – Pipeline by Les Laboratoires Servier SAS
      • Nash Pharmaceuticals Inc
        • Table Kidney Fibrosis – Pipeline by Nash Pharmaceuticals Inc
      • Novo Nordisk AS
        • Table Kidney Fibrosis – Pipeline by Novo Nordisk AS
      • Pharmaxis Ltd
        • Table Kidney Fibrosis – Pipeline by Pharmaxis Ltd
      • ProMetic Life Sciences Inc
        • Table Kidney Fibrosis – Pipeline by ProMetic Life Sciences Inc
      • Redx Pharma Plc
        • Table Kidney Fibrosis – Pipeline by Redx Pharma Plc
      • Regulus Therapeutics Inc
        • Table Kidney Fibrosis – Pipeline by Regulus Therapeutics Inc
      • Scholar Rock Inc
        • Table Kidney Fibrosis – Pipeline by Scholar Rock Inc
      • Sirnaomics Inc
        • Table Kidney Fibrosis – Pipeline by Sirnaomics Inc
      • Symic Biomedical Inc
        • Table Kidney Fibrosis – Pipeline by Symic Biomedical Inc
      • Vascular Biogenics Ltd
        • Table Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd
    • Polycystic Kidney Disease
      • Angion Biomedica Corp
        • Table Polycystic Kidney Disease – Pipeline by Angion Biomedica Corp
      • Celgene Corp
        • Table Polycystic Kidney Disease – Pipeline by Celgene Corp
      • Conatus Pharmaceuticals Inc
        • Table Polycystic Kidney Disease – Pipeline by Conatus Pharmaceuticals Inc
      • DiscoveryBiomed Inc
        • Table Polycystic Kidney Disease – Pipeline by DiscoveryBiomed Inc
      • Genzyme Corp
        • Table Polycystic Kidney Disease – Pipeline by Genzyme Corp
      • IC-MedTech Inc
        • Table Polycystic Kidney Disease – Pipeline by IC-MedTech Inc
      • Ipsen SA
        • Table Polycystic Kidney Disease – Pipeline by Ipsen SA
      • Kadmon Corp LLC
        • Table Polycystic Kidney Disease – Pipeline by Kadmon Corp LLC
      • ManRos Therapeutics
        • Table Polycystic Kidney Disease – Pipeline by ManRos Therapeutics
      • Mironid Ltd
        • Table Polycystic Kidney Disease – Pipeline by Mironid Ltd
      • NovaTarg Therapeutics Inc
        • Table Polycystic Kidney Disease – Pipeline by NovaTarg Therapeutics Inc
      • Q BioMed Inc
        • Table Polycystic Kidney Disease – Pipeline by Q BioMed Inc
      • Reata Pharmaceuticals Inc
        • Table Polycystic Kidney Disease – Pipeline by Reata Pharmaceuticals Inc
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Novartis AG
        • Table End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by Novartis AG
      • Prolong Pharmaceuticals LLC
        • Table End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by Prolong Pharmaceuticals LLC
      • VESSL Therapeutics Ltd
        • Table End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by VESSL Therapeutics Ltd
  • Dormant Projects
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects
    • Kidney Fibrosis
      • Table Kidney Fibrosis – Dormant Projects
    • Polycystic Kidney Disease
      • Table Polycystic Kidney Disease – Dormant Projects
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Table End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Dormant Projects
  • Discontinued Products
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Table Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products
    • Kidney Fibrosis
      • Table Kidney Fibrosis – Discontinued Products
    • Polycystic Kidney Disease
      • Table Polycystic Kidney Disease – Discontinued Products
    • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
      • Table End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Discontinued Products
  • Product Development Milestones
    • Chronic Kidney Disease (Chronic Renal Failure)
      • Featured News & Press Releases
    • Kidney Fibrosis
      • Featured News & Press Releases
    • Polycystic Kidney Disease
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report